Intrauterine insemination treatment in subfertility: an analysis of factors affecting outcome.
A total of 811 intrauterine insemination (IUI) cycles in which clomiphene citrate/human menopausal gonadotrophin (HMG) was used for ovarian stimulation were analysed retrospectively to identify prognostic factors regarding treatment outcome. The overall pregnancy rate was 12.6% per cycle, the multiple pregnancy rate 13.7%, and the miscarriage rate 23.5%. Logistic regression analysis revealed five predictive variables as regards pregnancy: number of the treatment cycle (P = 0.009), duration of infertility (P = 0.017), age (P = 0.028), number of follicles (P = 0.031) and infertility aetiology (P = 0.045). The odds ratios for age < 40 years, unexplained infertility aetiology (versus endometriosis) and duration of infertility < or = 6 years were 3.24, 2.79 and 2.33, respectively. A multifollicular ovarian response to clomiphene citrate/HMG resulted in better treatment success than a monofollicular response, and 97% of the pregnancies were obtained in the first four treatment cycles. The results indicate that clomiphene citrate/HMG/IUI is a useful and cost-effective treatment option in women < 40 years of age with infertility duration < or = 6 years, who do not suffer from endometriosis.
Nuojua-Huttunen
S
S
The Family Federation of Finland (The Oulu Infertility Clinic).
Tomas
C
C
Bloigu
R
R
Tuomivaara
L
L
Martikainen
H
H
D002996:Clomiphene / Q000627:therapeutic use; D003362:Cost-Benefit Analysis; D005260:Female; D017048:Health Care Costs; D006801:Humans; D007246:Infertility / Q000628:therapy*; D007317:Insemination, Artificial, Homologous / Q000191:economics; D016015:Logistic Models; D008297:Male; D008596:Menotropins / Q000627:therapeutic use; D010062:Ovulation Induction / Q000191:economics; D011247:Pregnancy; D011256:Pregnancy Outcome; D011272:Pregnancy, Multiple; D011379:Prognosis; D012189:Retrospective Studies
D002996:Clomiphene; D008596:Menotropins